Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Matthew Kurian

Breast Oncology · St Elizabeth Healthcare

View

Dr. Sarah Premji

Breast Oncology

View

Dr. Nerea Lopetegui-Lia

Breast Oncology · OSUMC

View

Dr. Allison Kurian

Breast Oncology · SU

View

Dr. Minhtri Nguyen

Breast Oncology · Advisor

View

Dr. Neil Iyengar

Breast Oncology · Emory University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    RLDr. Roberto Leon-Ferre
    Leading Voice

    Dr. Roberto Leon-Ferre

    Medical Oncology · Breast Oncology
    Mayo Clinic
    roberto
    Rochester, MN, USA

    Research

    The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen

    2025

    Via Breast Cancer Research and Treatment

    Research

    Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial

    2025

    Via Breast Cancer Research

    Aug 14, 2025Journal Article

    The Association of Clinical Stage at Presentation with Overall Survival of Patients who have HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy.

    ​

    Written by 1 Roon author & 3 others

    Via Annals of Surgical Oncology
    Aug 20, 2025Journal Article

    ASO Author Reflections: Survival of Patients with HER2-Positive Breast Cancer After Neoadjuvant Chemotherapy Based on Presenting Clinical Stage and Response to Neoadjuvant Chemotherapy.

    ​

    Written by 1 Roon author & 3 others

    Via Annals of Surgical Oncology
    Dec 1, 2025Journal Article

    ASO Visual Abstract: The Association of Clinical Stage at Presentation with Overall Survival in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy.

    ​

    Written by 1 Roon author & 3 others

    Via Annals of Surgical Oncology

    Research

    Identification of a Notch transcriptomic signature for breast cancer

    2024

    Via Breast Cancer Research

    Research

    Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer

    2024

    Via NPJ Breast Cancer

    Research

    Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

    2024

    Via JAMA

    Research

    Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial

    2024

    Via Clinical Cancer Research

    Research

    Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer

    2024

    Via Breast Cancer Research

    Jun 13, 2024Journal Article

    Impact of Presenting Stage on Overall Survival in Patients Treated with Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.

    ​

    Written by 1 Roon author & 3 others

    Via Annals of Surgical Oncology

    Research

    Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer

    2024

    Via Frontiers in Oncology

    Research

    Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy

    2024

    Via JAMA Oncology

    Research

    Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Triple-Negative Breast Cancer-Reply

    2024

    Via JAMA

    Research

    Current treatment paradigms for triple-negative breast cancer

    2024

    Via Minerva Medica